Charles River Laboratories International, Inc. logo
Charles River Laboratories International, Inc. (CRL)
Compare

Charles River Laboratories International, Inc. (CRL) Price History:24.55%(TTM)

Compare

The price cagr for Charles River Laboratories International, Inc. (CRL) is +24.55% over the latest trailing 12-month period. The comparable SPY value is +20.75%. Year-to-date price return is -7.10%. Price CAGR uses adjusted close price history and excludes dividends.

Current Price

$188.04

$-1.81 (-0.95%)

Previous Close: $189.85

Today's Trading

Open
$188.49
Day High
$193.81
Day Low
$184.42
Volume
307.71K
Avg Volume
N/A

52-Week Position

52%

of the 52-week price range

From 52-week high
-17.84%
From 52-week low
+31.44%

52-Week Price Range

52-Week Low

$143.06

Jun 17, 2025

Current Price

$188.04

52% of range

52-Week High

$228.88

Jan 21, 2026

Low (+31.44% from current)(-17.84% from current) High

Price Returns by Period

1 Day

-0.95%

7 Days

+4.54%

30 Days

+11.62%

YTD

-7.10%

1 Year

+24.53%

vs 52W High

-17.84%

CRL Price Chart

End-of-day pricesAdvanced chart →
CRL$188.04 24.44%as of Jun 10, 2026

Long-Term Performance (CAGR)

Price CAGR (3Y)

-1.65%

Price CAGR (5Y)

-11.93%

Total Return CAGR (3Y)

-1.65%

Total Return CAGR (5Y)

-11.93%

CAGR (Compound Annual Growth Rate) shows the annualized return over the specified period. Total Return includes dividends reinvested.

Key Price Statistics

Current Price$188.04
Previous Close$189.85
Day Range$184.42 - $193.81
52-Week Range$143.06 - $228.88
Volume307.71K
Average VolumeN/A
Market Cap$9.06B
% from 52W High-17.84%
Data as of Wednesday, June 10, 2026

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Wilmington, MA
18,700 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
James C. Foster